argenex (NASDAQ:ARGX - Get Free Report) is expected to post its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect argenex to post earnings of $4.34 per share and revenue of $909.8630 million for the quarter. Individuals can check the company's upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:30 AM ET.
argenex (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.90. argenex had a return on equity of 21.06% and a net margin of 40.98%.The firm had revenue of $866.79 million during the quarter, compared to the consensus estimate of $776.82 million. On average, analysts expect argenex to post $3 EPS for the current fiscal year and $11 EPS for the next fiscal year.
argenex Price Performance
NASDAQ:ARGX opened at $814.17 on Thursday. The firm has a market cap of $50.13 billion, a price-to-earnings ratio of 41.75, a price-to-earnings-growth ratio of 0.90 and a beta of 0.46. The firm's fifty day moving average price is $746.19 and its 200 day moving average price is $640.92. argenex has a 1-year low of $510.05 and a 1-year high of $855.46.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the business. Geneos Wealth Management Inc. lifted its stake in argenex by 550.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company's stock valued at $69,000 after buying an additional 99 shares in the last quarter. Rakuten Securities Inc. raised its holdings in shares of argenex by 113.1% in the second quarter. Rakuten Securities Inc. now owns 130 shares of the company's stock worth $72,000 after acquiring an additional 69 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of argenex by 60.2% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company's stock valued at $73,000 after acquiring an additional 50 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of argenex by 49.6% during the second quarter. EverSource Wealth Advisors LLC now owns 175 shares of the company's stock valued at $96,000 after acquiring an additional 58 shares during the last quarter. Finally, Quantbot Technologies LP increased its position in argenex by 120.1% during the 2nd quarter. Quantbot Technologies LP now owns 306 shares of the company's stock worth $169,000 after purchasing an additional 167 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
ARGX has been the topic of a number of recent analyst reports. Truist Financial boosted their price target on shares of argenex from $700.00 to $918.00 and gave the stock a "buy" rating in a research note on Monday, September 15th. Weiss Ratings reiterated a "hold (c)" rating on shares of argenex in a research report on Wednesday, October 8th. Stifel Nicolaus set a $882.00 price target on argenex in a report on Thursday, September 18th. Zacks Research upgraded argenex from a "hold" rating to a "strong-buy" rating in a research note on Monday, September 22nd. Finally, Jefferies Financial Group set a $818.00 price objective on argenex and gave the stock a "buy" rating in a research report on Tuesday, August 26th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, argenex presently has an average rating of "Buy" and an average price target of $817.53.
Read Our Latest Report on ARGX
About argenex
(
Get Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider argenex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenex wasn't on the list.
While argenex currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
